This study aimed to explore the role of clinical pharmacists in guiding nutritional treatment in a multi-disciplinary team for patients with ovarian cancer (OC) and the significance of pharmaceutical nutritional intervention in overall management and drug administration. Fifty-nine patients with OC in our gynaecological oncology ward were retrospectively investigated. The patients were divided into a conventional therapy (CT) group (n = 30) and a pharmaceutical management (PM) group (n = 29) according to different nutritional therapies received. Nutritional monitoring indicators and clinical response indicators were used to evaluate the intervention effect. Serum albumin (ALB), haemoglobin (HGB) and prealbumin (PAB) levels at admission and discharge, exhaust time, time to return to a normal diet, time to first postoperative chemotherapy and length of hospital stay were measured. The PAB and ALB indicators in the PM group returned to the admission levels; the difference between the two groups was statistically significant (p < 0.05). There was no significant difference in HGB levels between the two groups (p > 0.05). The time to flatus, time to return to normal diet and time to first postoperative chemotherapy in the PM group were significantly shorter than those in the CT group, and the differences had statistical significance (p < 0.05). Patients in the PM group had a significantly shorter hospital stay than those in the CT group (12.5 ± 3.2 days vs 16.8 ± 4.1 days; p = 0.022). Nutritional treatment management by clinical pharmacists plays a key role in the antitumour treatment of patients with OC, effectively improving their nutritional status and thus promoting rapid postoperative recovery.
Read full abstract